Menu Icon Search

New Diabetes and Hepatitis C medications now available to patients

August 14, 2018

As of the 1st of August 2018, the Australian Government have aimed to help improve the lives of those living with diabetes and Hepatitis C by making two treatments more affordable, helping patients save thousands of dollars a year.

As part of the Pharmaceutical Benefits Scheme (PBS), the excess of 170,000 Australians who face the many challenges and risks of living with Hepatitis C, are expected to benefit from the new listing of Maviret. Without this listing, patients could pay over $50,000 per course of treatment for this medicine.

Additionally, as a result of Ryzodeg now being listed on the Pharmaceutical Benefits Scheme, over 118,000 Australian adults living with both type 1 and 2 diabetes will be able to more easily regulate their blood sugar levels. Ryzodeg is the first diabetes pen to contain two types of insulin. 

These two new listings on the PBS will now mean that from August 1 patients will pay a maximum of $39.50 per script for these medications or just $6.40 per script for concessional patients, including pensioners.

The Federal Government also announced that it will provide $1 million to Hepatitis Australia to ‘continue education and awareness activities to improve hepatitis C testing and treatment uptake’.

Back to Latest Announcements

Icon Stay in the loop

Subscribe to our e-newsletter to stay up-to-date with news and information
affecting Health Care practitioners in the Darling Downs and West Moreton Regions: